

## Special Issue

# Immunogenicity of Botulinum Toxin

### Message from the Guest Editors

This Special Issue is aimed at describing the immunogenicity of botulinum neurotoxins (BoNT). BoNTs are clostridial products and form a family of highly specialized proteins that attack the mechanism of exocytosis in a variety of cells. Different components of BoNT can all induce immune responses. Therefore, the responses to BoNTs are not uniform, and a broad spectrum of responses is observed. Antibody formation can be life-saving on the one hand, and may be a therapy-limiting factor on the other hand. Several BoNTs have been tried for clinical applications. However, today only BoNT/A is mainly used for clinical applications owing to its long-lasting effect and low antigenicity. However, even for the development of clinically applicable preparations of botulinum neurotoxin type A (BoNT/A), attempts at purification and improvement in biological function and reduction of immunoresistance are absolutely necessary. Thus far, in all attempts, BoNT/A-treatment can still cause primary, secondary, partial or complete treatment failure. Knowledge of the course of disease before and after BoNT/A-therapy is important.

### Guest Editors

Dr. Sara Samadzadeh

1. Departments of Neurology, University of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany
2. Experimental and Clinical Research Center, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
3. Department of Regional Health Research and Molecular Medicine, University of Southern Denmark, Odense, Denmark
4. Department of Neurology, Slagelse Hospital, Slagelse, Denmark

Prof. Dr. Harald Hefter

Department of Neurology, University of Dusseldorf, Moorenstr 5, D-40225 Dusseldorf, Germany

### Deadline for manuscript submissions

30 April 2025



## Toxins

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 7.5  
Indexed in PubMed



[mdpi.com/si/154506](https://mdpi.com/si/154506)

*Toxins*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
toxins@mdpi.com

[mdpi.com/journal/  
toxins](https://mdpi.com/journal/toxins)





# Toxins

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.5  
Indexed in PubMed



[mdpi.com/journal/  
toxins](https://mdpi.com/journal/toxins)



## About the Journal

### Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

---

### Editor-in-Chief

Prof. Dr. Jay Fox

Department of Microbiology, University of Virginia, Charlottesville, VA,  
USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

#### Journal Rank:

JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.9 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the first half of 2024).